Journal of Cardiovascular Disease Research
A comparative study on efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction age related
Dr. Kunal Sahai, Dr. Deepak Gupta, Dr. Devopam Roy
JCDR. 2023: 4041-4045
Abstract
The DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies reduced the risk of mortality and heart failure hospitalization and improved symptoms in patients with heart failure and reduced ejection fraction. We examined the effects of dapagliflozin according to age, given potential concerns about the efficacy and safety of therapies in the elderly. Materials and Methods: This study done in Dept. Of General Medicine and Pulmonary Medicine , Naraina Medical College and Research Centre, Kanpur,(Dec 2021 to Nov 2022) Men and women aged 18 years or older with a diagnosis of HF for at least 2 months Results: In our study 350 (43.6%) Patients had a non-ischaemic aetiology ,327 (35.6%) with known ischaemic aetiology (8.1%) with ‘unknown’ aetiology assumed to be non-ischaemic, as pre-specified in the analysis plan
» PDF